Table 2 and Table 3.
Association between a discharge prescription for angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs) and post-discharge outcomes in a propensity-matched cohorts of nursing home resident Medicare beneficiaries hospitalized for decompensated heart failure
| 30-day outcomes | % (events) |
Absolute risk difference* | Hazard ratio† (95% confidence interval) |
|
|---|---|---|---|---|
| Use of ACEIs or ARBs | ||||
| AHFP Cohort | No (n=157) | Yes (n=157) | ||
| 30-day outcomes | ||||
| All-cause readmission | 22% (35) | 18% (28) | −4% | 0.78 (0.47−1.28) |
| Heart failure readmission | 8% (13) | 6% (9) | −2% | 0.68 (0.29−1.60) |
| All-cause mortality | 13% (20) | 16% (25) | +3% | 1.26 (0.70−2.27) |
| All-cause mortality or all-cause readmission | 34% (54) | 31% (48) | −3% | 0.86 (0.58−1.27) |
| 1-year outcomes | ||||
| All-cause readmission | 62% (97) | 52% (82) | −10% | 0.76 (0.56−1.02) |
| Heart failure readmission | 27% (42) | 18% (28) | −9% | 0.68 (0.42−1.09) |
| All-cause mortality | 62% (97) | 61% (96) | −1% | 1.04 (0.78−1.38) |
| All-cause mortality or all-cause readmission | 89% (139) | 82% (129) | −7% | 0.84 (0.66−1.06) |
|
| ||||
| AHFP + OPTIMIZE-HF Cohorts | No (n=367) | Yes (n=367) | ||
| 30-day outcomes | ||||
| All-cause readmission | 24% (87) | 23% (84) | −1% | 0.94 (0.70−1.27) |
| Heart failure readmission | 8% (28) | 7% (26) | −1% | 0.92 (0.54−1.57) |
| All-cause mortality | 16% (58) | 14% (52) | −2% | 0.89 (0.61−1.30) |
| All-cause mortality or all-cause readmission | 35% (130) | 33% (121) | −2% | 0.91 (0.71−1.16) |
| 1-year outcomes | ||||
| All-cause readmission | 64% (235) | 63% (230) | −1% | 0.95 (0.79−1.14) |
| Heart failure readmission | 26% (97) | 25% (91) | −1% | 0.94 (0.71−1.25) |
| All-cause mortality | 60% (97) | 60% (96) | 0% | 0.99 (0.82−1.19) |
| All-cause mortality or all-cause readmission | 87% (319) | 86% (315) | −1% | 0.96 (0.82−1.12) |
*
Absolute risk differences were calculated by subtracting percent events in patients receiving no ACEIs or ARBs from those receiving those drugs
†
The hazard ratios compared patients receiving ACEIs or ARBs versus those not receiving those drugs. These hazard ratios were calculated by treating patients without events during the first 30 days as censored.